Table 2 Univerate analysis of medication use, dose, and maximum dose achieved and risk of SRC
From: Systemic sclerosis medications and risk of scleroderma renal crisis
SRC (n = 31) | SSc without SRC (n = 322) | P-Value | |
|---|---|---|---|
Medication Use | |||
ACE Inhibitor | 77 (24/31) | 33 (108/332) | < 0.001 |
ARB | 13 (4/31) | 16 (53/322) | NS |
ACE inhibitor or ARB | 84 (26/31) | 40 (128/322) | < 0.001 |
CCB (dihydropyridine) | 65 (20/31) | 66 (214/322) | NS |
CCB (non-dihydropyridine) | 6 (2/31) | 4 (322) | NS |
CCB (any) | 65 (20/31) | 70 (226/322) | NS |
Endothelin Receptor Blocker (ERB) | 6 (2/31) | 3 (9/322) | NS |
Mycophenolic Mofetil (MMF) | 16 (5/31) | 11 (36/322) | NS |
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) | 84 (26/31) | 77 (249/322) | NS |
Fluticasone | 42 (13/31) | 56 (180/322) | NS |
Doubling of Dose | |||
ACE Inhibitor | 61 (19/31) | 12 (38/322) | P < 0.001 |
ARB | 3 (1/31) | 3 (10/322) | NS |
ACE inhibitor or ARB | 61 (19/31) | 14 (45/322) | NS |
CCB (dihydropyridine) | 32 (10/31) | 23 (73/322) | NS |
CCB (non-dihydropyridine) | 0 (0/31) | 3 (10/322) | NS |
CCB (any) | 32 (10/31) | 25 (80/322) | NS |
Achieve Max Dose | |||
ACE Inhibitor | 45 (14/31) | 4 (14/322) | < 0.001 |
ARB | 10 (3/31) | 2 (8/322) | 0.06 |
ACE inhibitor or ARB | 45 (19/31) | 7 (21/322) | < 0.001 |
CCB (dihydropyridine) | 19 (6/31) | 16 (50/322) | NS |
CCB (non-dihydropyridine) | 3 (1/31) | 3 (10/322) | NS |
CCB (any) | 19 (6/31) | 16 (52/322) | NS |